The global cost of epilepsy: A systematic review and extrapolation

Abstract

Objective

Global action for epilepsy requires information on the cost of epilepsy, which is currently unknown for most countries and regions of the world. To address this knowledge gap, the International League Against Epilepsy Commission on Epidemiology formed the Global Cost of Epilepsy Task Force.

Methods

We completed a systematic search of the epilepsy cost-of-illness literature and identified studies that provided a comprehensive set of direct health care and/or indirect costs, followed standard methods of case identification and cost estimation, and used data ...

Seguir leyendo →
0

Real‐world user experience with seizure detection wearable devices in the home environment

Abstract

Objective

To evaluate direct user experience with wearable seizure detection devices in the home environment.

Methods

A structured online questionnaire was completed by 242 users (175 caregivers and 67 persons with epilepsy), most of the patients (87.19%) having tonic–clonic seizures.

Results

The vast majority of the users were overall satisfied with the wearable device, considered that using the device was easy, and agreed that the use of the device improved their quality of life (median = 6 on 7-point Likert scale). A high retention rate ...

Seguir leyendo →
0

Multicenter, cross‐sectional study of the costs of illness and cost‐driving factors in adult patients with epilepsy

Abstract

Objective

This study was undertaken to quantify epilepsy-related costs of illness (COI) in Germany and identify cost-driving factors.

Methods

COI were calculated among adults with epilepsy of different etiologies and severities. Multiple regression analysis was applied to determine any epilepsy-related and sociodemographic factors that serve as cost-driving factors.

Results

In total, 486 patients were included, with a mean age of 40.5 ± 15.5 years (range = 18–83 years, 58.2% women). Mean 3-month COI were estimated at €4911, €2782, and €2598 for focal, genetic generalized, and unclassified epilepsy, respectively. The ...

Seguir leyendo →
0

Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects

Abstract

Objective

As a key member of the transient receptor potential (TRP) superfamily, TRP canonical 3 (TRPC3) regulates calcium homeostasis and contributes to neuronal excitability. Ablation of TRPC3 lessens pilocarpine-induced seizures in mice, suggesting that TRPC3 inhibition might represent a novel antiseizure strategy. Among current TRPC3 inhibitors, pyrazole 3 (Pyr3) is most selective and potent. However, Pyr3 only provides limited benefits in pilocarpine-treated mice, likely due to its low metabolic stability and potential toxicity. We recently reported a modified pyrazole compound 20 (or JW-65) ...

Seguir leyendo →
0

PIGN encephalopathy: Characterizing the epileptology

Abstract

Objective

Epilepsy is common in patients with PIGN diseases due to biallelic variants; however, limited epilepsy phenotyping data have been reported. We describe the epileptology of PIGN encephalopathy.

Methods

We recruited patients with epilepsy due to biallelic PIGN variants and obtained clinical data regarding age at seizure onset/offset and semiology, development, medical history, examination, electroencephalogram, neuroimaging, and treatment. Seizure and epilepsy types were classified.

Results

Twenty six patients (13 female) from 26 families were identified, with mean age 7 years (range = 1 month to 21 years; three ...

Seguir leyendo →
0

Automated detection of absence seizures using a wearable EEG device: a phase‐3 validation study and feasibility of automated behavioral testing

Summary

Objective

Our primary goal was to measure the accuracy of fully automated absence seizure detection, using a wearable EEG device. As a secondary goal, we also tested the feasibility of automated behavioral testing triggered by the automated detection.

Methods

We conducted a phase-3 clinical trial (NCT04615442), with a prospective, multicenter, blinded study design. The input was the one-channel EEG recorded with dry electrodes embedded into a wearable headband device connected to a smartphone. The seizure detection algorithm was developed using artificial intelligence (convolutional ...

Seguir leyendo →
0

Effect of levetiracetam on the gene expression of placental transporters in a murine model

Abstract

Objective

Levetiracetam (LEV) is an antiseizure medication prescribed to women during childbearing age. The impact of LEV on placental transporters is poorly understood. This study aimed to assess the effect of LEV exposure on the messenger RNA (mRNA) expression of placental transporters for hormones and nutrients and to correlate their expression with the drug’s serum concentration in pregnant mice.

Methods

Studies were conducted on gestational days (GD) 13 and 18, following oral treatment with 100 mg/kg LEV or the vehicle every 24 h after weaning. ...

Seguir leyendo →
0

Behavioral phenotypes of pediatric temporal lobe epilepsy

Abstract

Objective

A broad spectrum of emotional-behavioral problems have been reported in pediatric temporal lobe epilepsy (TLE), but with considerable variability in their presence and nature of expression, which hampers precise identification and treatment. The present study aimed to empirically identify latent patterns or behavioral phenotypes and their correlates.

Methods

Data included parental ratings of emotional-behavioral status on the Behavior Assessment System for Children, 2nd Edition (BASC-2) of 81 children (mean age = 11.79, standard deviation [SD] = 3.93) with TLE. The nine clinical subscales were subjected to ...

Seguir leyendo →
0

Time to Onset of Cannabidiol (CBD) Treatment Effect and Resolution of Adverse Events in Tuberous Sclerosis Complex: Post Hoc Analysis of Randomized Controlled Phase 3 Trial GWPCARE6

Summary

Objective

To estimate the timing of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]) onset, we conducted a post hoc analysis of GWPCARE6 (NCT02544763), a randomized, placebo-controlled, phase 3 trial in patients with drug-resistant epilepsy associated with tuberous sclerosis complex (TSC).

Methods

Patients received plant-derived pharmaceutical formulation of highly purified CBD (Epidiolex®; 100 mg/mL oral solution) at 25 mg/kg/day (CBD25) or 50 mg/kg/day (CBD50) or placebo for 16 weeks (4-week titration, 12-week maintenance). Treatment started at 5 mg/kg/day for all groups ...

Seguir leyendo →
0

Potential role of regulatory DNA variants in modifying the risk of severe cutaneous reactions induced by aromatic anti‐seizure medications

Abstract

Objective

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse drug reactions. Antiseizure medications (ASMs) with aromatic ring structure, including carbamazepine, are among the most common culprits. Screening for human leukocyte antigen (HLA) allele HLAB*15:02 is recommended prior to initiating treatment with carbamazepine in Asians, but this allele has low positive predictive value.

Methods

We performed whole genome sequencing and analyzed 6 199 696 common variants among 113 aromatic ASM-induced SJS/TEN cases and 84 tolerant controls of Han Chinese ethnicity.

Results

In the primary ...

Seguir leyendo →
0
Página 62 de 225 «...3040506061626364...»